Brokerages Set Natera, Inc. (NASDAQ:NTRA) PT at $101.19

Shares of Natera, Inc. (NASDAQ:NTRA) have earned a consensus rating of “Buy” from the fifteen research firms that are currently covering the company, MarketBeat.com reports. Fifteen analysts have rated the stock with a buy rating. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $103.27.

A number of equities research analysts have recently issued reports on the stock. StockNews.com raised shares of Natera from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. BTIG Research boosted their price objective on Natera from $100.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, May 13th. TD Cowen raised their target price on shares of Natera from $123.00 to $137.00 and gave the stock a “buy” rating in a research note on Friday, May 10th. Canaccord Genuity Group lifted their price target on shares of Natera from $100.00 to $130.00 and gave the company a “buy” rating in a report on Friday, May 10th. Finally, Jefferies Financial Group began coverage on shares of Natera in a research report on Monday, June 3rd. They set a “buy” rating and a $142.00 price objective on the stock.

Insider Buying and Selling at Natera

In related news, insider Daniel Rabinowitz sold 30,000 shares of the stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $104.59, for a total value of $3,137,700.00. Following the completion of the transaction, the insider now owns 204,495 shares of the company’s stock, valued at approximately $21,388,132.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Natera news, insider Daniel Rabinowitz sold 30,000 shares of Natera stock in a transaction on Friday, May 10th. The shares were sold at an average price of $104.59, for a total transaction of $3,137,700.00. Following the completion of the transaction, the insider now directly owns 204,495 shares of the company’s stock, valued at $21,388,132.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Michael Burkes Brophy sold 1,866 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $99.65, for a total transaction of $185,946.90. Following the completion of the sale, the chief financial officer now directly owns 71,955 shares in the company, valued at approximately $7,170,315.75. The disclosure for this sale can be found here. Insiders sold 118,387 shares of company stock worth $12,684,836 over the last 90 days. 7.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Natera

Several institutional investors have recently made changes to their positions in NTRA. Norges Bank acquired a new stake in Natera in the fourth quarter valued at approximately $83,970,000. Perceptive Advisors LLC boosted its position in Natera by 289.7% during the fourth quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock worth $53,258,000 after purchasing an additional 632,047 shares in the last quarter. Vanguard Group Inc. increased its holdings in Natera by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock worth $687,280,000 after acquiring an additional 588,147 shares in the last quarter. First Light Asset Management LLC lifted its stake in Natera by 295.9% in the 1st quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock valued at $60,063,000 after buying an additional 490,822 shares in the last quarter. Finally, Farallon Capital Management LLC raised its stake in Natera by 13.0% in the 1st quarter. Farallon Capital Management LLC now owns 3,927,683 shares of the medical research company’s stock valued at $359,226,000 after purchasing an additional 452,800 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Price Performance

Shares of NTRA opened at $97.91 on Thursday. The firm has a market cap of $12.02 billion, a PE ratio of -31.38 and a beta of 1.48. Natera has a 1-year low of $36.90 and a 1-year high of $117.23. The company has a current ratio of 4.12, a quick ratio of 3.98 and a debt-to-equity ratio of 0.36. The firm has a fifty day simple moving average of $108.39 and a two-hundred day simple moving average of $94.05.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.16. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The business had revenue of $367.70 million for the quarter, compared to analysts’ expectations of $316.31 million. During the same period last year, the firm posted ($1.23) earnings per share. The business’s revenue for the quarter was up 52.1% on a year-over-year basis. On average, equities analysts anticipate that Natera will post -2.43 EPS for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.